Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Libby MD
Peter Libby MD Advisory Board
Ileana Piña MD, MPH, FAHA, FACC
Ileana L. Piña MD, MPH, FAHA, FACC Advisory Board
Paul Thompson MD
Paul D. Thompson MD Advisory Board
See All Experts
story of the week
Published in Cardiology and
1 other channel

Journal Scan / Research · June 02, 2024

Long-Term Kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease

Nature

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Lin MD, CCFP

Giselle Suero-Abreu MD, PhD, MSc

Nature
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Nature 2024 May 25;[EPub Ahead of Print], HM Colhoun, I Lingvay, PM Brown, J Deanfield, K Brown-Frandsen, SE Kahn, J Plutzky, K Node, A Parkhomenko, L Rydén, JPH Wilding, JFE Mann, KR Tuttle, T Idorn, N Rathor, AM Lincoff

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated